Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Doxorubicin + Ifosfamide in Advanced STS
NCT04012827Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04012827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012827.